Letrozole Tablet
NDC 50090-8002
Product Information
Letrozole is a ANDA-approved product labeled by A-s Medication Solutions. This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. It is supplied as a yellow tablet for oral administration. This product entry covers the primary NDC 50090-8002 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
N;L
Code Structure Chart
Product Details
What is NDC 50090-8002?
What are the uses of this product?
What are Active Ingredients of this product?
- LETROZOLE 2.5 mg/1 - A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LETROZOLE (UNII: 7LKK855W8I)
- LETROZOLE (UNII: 7LKK855W8I) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- SILICA (UNII: ETJ7Z6XBU4)
- CI 77891 (UNII: 15FIX9V2JP)
- CI 77492 (UNII: EX438O2MRT)
- STARCH, CORN (UNII: O8232NY3SJ)
- TALC (UNII: 7SEV7J4R1U)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.